




Mainland adjusts import and export duties for range of products

In promulgating the 2023 Tariff Adjustment Plan, Mainland China has imposed a provisional import tax rate lower than the most-favoured-nation (MFN) tariff rate on 1,020 products. It will also reduce the MFN tax rate on 62 types of information technology products from 1 July 2023. The adjustments mean that the mainland's overall tariff level will drop from 7.4% to 7.3%. (China Daily)



Mainland drops foreign trade operator registration filing requirements

The mainland has recently abolished registration filing requirements for foreign trade operators. This means that companies applying for import and export licences, in addition to technology import and export contract registration certificates, quotas, state trade qualifications and other relevant certificates and qualifications, will no longer be required to go through registration filing procedures. (Xinhua)



In a bid to advance reforms in the drug marketing licence system in the GBA, Nansha District, Guangzhou is launching measures to build a new manufacturing-marketing model for drugs and medical devices originating from Hong Kong and Macao. In particular, a "green channel" will be established to attract qualified Hong Kong and Macao enterprises to Nansha and boost the commercialisation of research and development (R&D) results.

(China News Service; in Chinese only)



Foshan policies support new life science park

Foshan has unveiled dedicated new policies to support the city's 10 major industrial parks and encourage innovation-led manufacturing. The policies are focused on the development of the Yundonghai Life Science Park. As the only biomedicine industrial park in the GBA offering more than 6.67 million square metres of land for development, Yundonghai will provide subsidies of up to Rmb100 million to enterprises that set up operations there. (Nanfang Daily; in Chinese only)



Shenzhen promotes development of cell and gene industry

Following its publication of regulations on the promotion of the cell and gene industry, Shenzhen has become the first mainland city to enact laws related to the development of this industry. The regulations will allow, upon review and approval, cell and gene drugs currently undergoing clinical trials to be used on other patients. (<u>21st Century Business Herald</u>; in Chinese only)